NCT04983238 - Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

April 19, 2023

Study Completion Date

June 26, 2023

Conditions

Metastatic Breast Cancer

Interventions

DRUG

BYON5667 & SYD985

Ocular administration: BYON5667, Intravenous administration: SYD985

DRUG

Placebo & SYD985

Ocular administration: Placebo, Intravenous administration: SYD985

Trial Locations (10)

University Hospital Antwerp, Antwerp

UZ Leuven, Leuven

Vall d' Hebron, Barcelona

ICO I'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat

Hospital Universitari Arnau de Vilanova, Lleida

START Madrid HU Fundacion Jimenez Diaz, Madrid

START Madrid HU HM Sanchinarro, Madrid

Institut Bergonié, Bordeaux

Centre Oscar Lambret, Lille

Hôpital Saint Louis, Paris